This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
IDEXX (IDXX) Earnings Beat Estimates in Q1, '21 View Up
by Zacks Equity Research
IDEXX (IDXX) registers strong contribution from its CAG business in the first quarter despite pandemic-induced challenges.
Orthofix's (OFIX) Q1 Earnings Top Estimates, 2021 View Up
by Zacks Equity Research
Strong sales of Orthofix's (OFIX) M6-C artificial disc and FITBONE lengthening nail drive its Q1 top line.
CONMED (CNMD) Surges 4.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
CONMED (CNMD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
CONMED (CNMD) Earnings and Revenue Surpass Estimates in Q1
by Zacks Equity Research
CONMED (CNMD) witnesses growth in revenues in both its segments during Q1.
Conmed (CNMD) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Conmed (CNMD) delivered earnings and revenue surprises of 46.51% and 7.01%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Conmed (CNMD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
Investor optimism is high on CONMED (CNMD) stock, courtesy of its solid prospects.
CONMED (CNMD) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Despite weak segmental performance in fourth quarter, CONMED (CNMD) showed strength and resilience in amid a tough operating environment.
Conmed (CNMD) Q4 Earnings Surpass Estimates
by Zacks Equity Research
Conmed (CNMD) delivered earnings and revenue surprises of 7.69% and -3.91%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
MCK or CNMD: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MCK vs. CNMD: Which Stock Is the Better Value Option?
LH or CNMD: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
LH vs. CNMD: Which Stock Is the Better Value Option?
Here's Why You Should Hold on to CONMED (CNMD) Stock for Now
by Zacks Equity Research
Investor confidence is high on CONMED (CNMD) stock, thanks to solid prospects.
LH or CNMD: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
LH vs. CNMD: Which Stock Is the Better Value Option?
LH vs. CNMD: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
LH vs. CNMD: Which Stock Is the Better Value Option?
CONMED (CNMD) Earnings and Revenues Surpass Estimates in Q3
by Zacks Equity Research
CONMED's (CNMD) General Surgery unit witnessed revenue growth in Q3
Conmed (CNMD) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Conmed (CNMD) delivered earnings and revenue surprises of 252.00% and 16.07%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Conmed (CNMD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Avoid Betting on Integer Holdings Now
by Zacks Equity Research
Stiff competition in the MedTech space and weak segmental and operational performance weighs on Integer Holdings (ITGR).
Cerner Inks Deal to Simplify Advance Care Planning Procedure
by Zacks Equity Research
Cerner's (CERN) partners with Vynca to simplify advance care planning process, thereby enabling patients and clinicians to discuss and make critical end-of-life decisions.
Here's Why You Should Hold on to CONMED (CNMD) Stock for Now
by Zacks Equity Research
Investor confidence is high on CONMED (CNMD) stock, thanks to solid prospects.
PDCO vs. CNMD: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PDCO vs. CNMD: Which Stock Is the Better Value Option?
CONMED (CNMD) Q2 Loss Narrower Than Expected, Revenues Top
by Zacks Equity Research
CONMED's (CNMD) core units - General Surgery and Orthopedic Surgery - witnessed revenue decline in Q2.
Conmed (CNMD) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Conmed (CNMD) delivered earnings and revenue surprises of 93.14% and 22.20%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy CONMED (CNMD) Ahead of Earnings?
by Zacks Equity Research
CONMED (CNMD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Why Conmed (CNMD) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Conmed (CNMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.